<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00714077</url>
  </required_header>
  <id_info>
    <org_study_id>CAMS_rectal cancer_01</org_study_id>
    <nct_id>NCT00714077</nct_id>
  </id_info>
  <brief_title>Adjuvant Treatment of Concurrent RT and CAPOX or Capecitabine Alone for Stage II and III Rectal Cancer</brief_title>
  <official_title>Prospective Randomized Phase III Study of Concurrent Capecitabine and Radiotherapy With or Without Oxaliplatin as Adjuvant Treatment for Stage II and III Rectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese Academy of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Zhejiang Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cancer Hospital of Guizhou Province</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shandong Cancer Hospital and Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hebei Medical University Fourth Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Peking University Third Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>General Hospital of Chinese Armed Police Forces</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Chinese Academy of Medical Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is:

        -  To compare the long-term of survival and local/regional control between the two
           postoperative concurrent chemoradiotherapy regimens: capecitabine vs. oxaliplatin and
           capecitabine,for stage II and III rectal cancer

        -  To compare the toxicity profile between the two different concurrent chemoradiotherapy
           regimens.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Adjuvant 5-FU based concurrent chemoradiotherapy and chemotherapy is the standard care for
      locally advanced stage II-III rectal cancer, based on several randomized Phase III clinical
      trials. With this standard treatment, 5-year local failure rate and distant metastasis rate
      is 10% and around 35%, respectively. Capecitabine, an analog of 5-fluoruracil (5FU), was
      demonstrated to have similar treatment results compared to 5-FU, but have much lower
      toxicities. Oxaliplatin based chemotherapy, also showed a better disease-free survival rate
      compared with 5-FU based-regimen. So far, some Phase I/II studies have shown the safety and
      preliminary results of either concurrent chemotherapy of capecitabine or oxaliplatin and
      capecitabine. The long-term results in comparison of capecitabine concurrent
      chemoradiotherapy with oxaliplatin/capecitabine concurrent chemoradiotherapy need to be
      further analyzed.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2008</start_date>
  <completion_date type="Anticipated">June 2018</completion_date>
  <primary_completion_date type="Anticipated">January 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>3-year disease free survival rate</measure>
    <time_frame>the day of surgery to the date of the event</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall survival rate</measure>
    <time_frame>the day of surgery to the date of death or last follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cumulative incidence of local recurrence</measure>
    <time_frame>the day of surgery to the date of local recurrence</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cumulative incidence of distant metastasis</measure>
    <time_frame>the day of surgery to the date of distant metastasis</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>compliance</measure>
    <time_frame>during adjuvant radiotherapy and chemotherapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>safety</measure>
    <time_frame>the day of randomization to the date of death or last follow-up</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">570</enrollment>
  <condition>Rectal Neoplasms</condition>
  <arm_group>
    <arm_group_label>adjuvant capecitabine</arm_group_label>
    <description>To compare different adjuvant concurrent chemoradiotherapy regimen (Oxaliplatin with capecitabine vs capecitabine) for patients with II/III rectal cancer</description>
  </arm_group>
  <arm_group>
    <arm_group_label>adjuvant oxaliplatin and capecitabine</arm_group_label>
    <description>To compare different adjuvant concurrent chemoradiotherapy regimen (Oxaliplatin with capecitabine vs capecitabine) for patients with II/III rectal cancer</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Multicenter patients enrollment
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18-75 years old,male or female

          -  R0 surgery

          -  Pathologically approved as stage II or stage III

          -  Enrolled within 6 months from the date of surgery

          -  Upper border of tumor before surgery was under L5

          -  KPS&gt;70% or ECOG 0-2

          -  No prior radiotherapy in the past 6 months

          -  Received chemotherapy no more than 4 cycles after surgery

          -  HGB&gt;100 g/L, WBC≥3.5x109 /L, PLT≥100x109 /L; CR&lt;1.5 x Upper normality，TB&lt;2.5 X Upper
             normality，AST or ALT&lt;2.5 x Upper normality，AKP&lt;2.5 X Upper normality

          -  Signed consent

        Exclusion Criteria:

          -  Other malignancies simultaneously except in situ cervix or nonmelanoma skin cancer

          -  Pregnancy or in lactation

          -  HGB&lt;100 g/L, WBC&lt;3.5x109 /L, PLT&lt;100x109 /L; CR≥1.5 x Upper normality，TB≥2.5 X Upper
             normality，AST or ALT≥2.5 x Upper normality，AKP≥2.5 X Upper normality
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yexiong Li, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>CAMS</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jing Jin, M.D.;Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>CAMS</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jing Jin, M.D.</last_name>
    <phone>861087788280</phone>
    <email>jingjin1025@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yexiong Li, M.D.</last_name>
    <phone>861087788860</phone>
    <email>yexiong12@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Jing Jin</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jing Jin, M.D.</last_name>
      <phone>8610-87788280</phone>
      <email>jingjin1025@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Yexiong Li, M.D.</last_name>
      <phone>8610-87788860</phone>
      <email>yexiong12@163.com</email>
    </contact_backup>
    <investigator>
      <last_name>Jing Jin, M.D.;Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jing Jin</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jing Jin, M.D.</last_name>
      <phone>8610-87788280</phone>
      <email>jingjin25@yahoo.com.cn</email>
    </contact>
    <contact_backup>
      <last_name>Yexiong Li, M.D.</last_name>
      <phone>8610-87788860</phone>
      <email>yexiong3@yahoo.com.cn</email>
    </contact_backup>
    <investigator>
      <last_name>Jing Jin, M.D.;Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Tveit KM, Guldvog I, Hagen S, Trondsen E, Harbitz T, Nygaard K, Nilsen JB, Wist E, Hannisdal E. Randomized controlled trial of postoperative radiotherapy and short-term time-scheduled 5-fluorouracil against surgery alone in the treatment of Dukes B and C rectal cancer. Norwegian Adjuvant Rectal Cancer Project Group. Br J Surg. 1997 Aug;84(8):1130-5.</citation>
    <PMID>9278661</PMID>
  </reference>
  <reference>
    <citation>Wolmark N, Wieand HS, Hyams DM, Colangelo L, Dimitrov NV, Romond EH, Wexler M, Prager D, Cruz AB Jr, Gordon PH, Petrelli NJ, Deutsch M, Mamounas E, Wickerham DL, Fisher ER, Rockette H, Fisher B. Randomized trial of postoperative adjuvant chemotherapy with or without radiotherapy for carcinoma of the rectum: National Surgical Adjuvant Breast and Bowel Project Protocol R-02. J Natl Cancer Inst. 2000 Mar 1;92(5):388-96.</citation>
    <PMID>10699069</PMID>
  </reference>
  <reference>
    <citation>Gastrointestinal Tumor Study Group. Prolongation of the disease-free interval in surgically treated rectal carcinoma. N Engl J Med. 1985 Jun 6;312(23):1465-72.</citation>
    <PMID>2859523</PMID>
  </reference>
  <reference>
    <citation>Krook JE, Moertel CG, Gunderson LL, Wieand HS, Collins RT, Beart RW, Kubista TP, Poon MA, Meyers WC, Mailliard JA, et al. Effective surgical adjuvant therapy for high-risk rectal carcinoma. N Engl J Med. 1991 Mar 14;324(11):709-15.</citation>
    <PMID>1997835</PMID>
  </reference>
  <reference>
    <citation>de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, Boni C, Cortes-Funes H, Cervantes A, Freyer G, Papamichael D, Le Bail N, Louvet C, Hendler D, de Braud F, Wilson C, Morvan F, Bonetti A. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 2000 Aug;18(16):2938-47.</citation>
    <PMID>10944126</PMID>
  </reference>
  <reference>
    <citation>Giacchetti S, Perpoint B, Zidani R, Le Bail N, Faggiuolo R, Focan C, Chollet P, Llory JF, Letourneau Y, Coudert B, Bertheaut-Cvitkovic F, Larregain-Fournier D, Le Rol A, Walter S, Adam R, Misset JL, Lévi F. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol. 2000 Jan;18(1):136-47.</citation>
    <PMID>10623704</PMID>
  </reference>
  <reference>
    <citation>Adjuvant chemotherapy with oxaliplatin, in combination with fluorouracil plus leucovorin prolongs disease-free survival, but causes more adverse events in people with stage II or III colon cancer Abstracted from: Andre T, Boni C, Mounedji-Boudiaf L, et al. Multicenter international study of oxaliplatin/5-fluorouracil/leucovorin in the adjuvant treatment of colon cancer (MOSAIC) investigators. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004;350:2343-51. Cancer Treat Rev. 2004 Dec;30(8):711-3.</citation>
    <PMID>15541581</PMID>
  </reference>
  <reference>
    <citation>Van Cutsem E, Hoff PM, Harper P, Bukowski RM, Cunningham D, Dufour P, Graeven U, Lokich J, Madajewicz S, Maroun JA, Marshall JL, Mitchell EP, Perez-Manga G, Rougier P, Schmiegel W, Schoelmerich J, Sobrero A, Schilsky RL. Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials. Br J Cancer. 2004 Mar 22;90(6):1190-7.</citation>
    <PMID>15026800</PMID>
  </reference>
  <reference>
    <citation>Twelves C, Wong A, Nowacki MP, Abt M, Burris H 3rd, Carrato A, Cassidy J, Cervantes A, Fagerberg J, Georgoulias V, Husseini F, Jodrell D, Koralewski P, Kröning H, Maroun J, Marschner N, McKendrick J, Pawlicki M, Rosso R, Schüller J, Seitz JF, Stabuc B, Tujakowski J, Van Hazel G, Zaluski J, Scheithauer W. Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med. 2005 Jun 30;352(26):2696-704.</citation>
    <PMID>15987918</PMID>
  </reference>
  <reference>
    <citation>Sawada N, Ishikawa T, Sekiguchi F, Tanaka Y, Ishitsuka H. X-ray irradiation induces thymidine phosphorylase and enhances the efficacy of capecitabine (Xeloda) in human cancer xenografts. Clin Cancer Res. 1999 Oct;5(10):2948-53.</citation>
    <PMID>10537364</PMID>
  </reference>
  <reference>
    <citation>Cividalli A, Ceciarelli F, Livdi E, Altavista P, Cruciani G, Marchetti P, Danesi DT. Radiosensitization by oxaliplatin in a mouse adenocarcinoma: influence of treatment schedule. Int J Radiat Oncol Biol Phys. 2002 Mar 15;52(4):1092-8.</citation>
    <PMID>11958906</PMID>
  </reference>
  <reference>
    <citation>Kim JC, Kim TW, Kim JH, Yu CS, Kim HC, Chang HM, Ryu MH, Park JH, Ahn SD, Lee SW, Shin SS, Kim JS, Choi EK. Preoperative concurrent radiotherapy with capecitabine before total mesorectal excision in locally advanced rectal cancer. Int J Radiat Oncol Biol Phys. 2005 Oct 1;63(2):346-53.</citation>
    <PMID>15913913</PMID>
  </reference>
  <reference>
    <citation>Kuebler JP, Wieand HS, O'Connell MJ, Smith RE, Colangelo LH, Yothers G, Petrelli NJ, Findlay MP, Seay TE, Atkins JN, Zapas JL, Goodwin JW, Fehrenbacher L, Ramanathan RK, Conley BA, Flynn PJ, Soori G, Colman LK, Levine EA, Lanier KS, Wolmark N. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J Clin Oncol. 2007 Jun 1;25(16):2198-204. Epub 2007 Apr 30.</citation>
    <PMID>17470851</PMID>
  </reference>
  <reference>
    <citation>Jin J, Li YX, Liu YP, Wang WH, Song YW, Li T, Li N, Yu ZH, Liu XF. A phase I study of concurrent radiotherapy and capecitabine as adjuvant treatment for operable rectal cancer. Int J Radiat Oncol Biol Phys. 2006 Mar 1;64(3):725-9. Epub 2005 Oct 19.</citation>
    <PMID>16242260</PMID>
  </reference>
  <reference>
    <citation>Souglakos J, Androulakis N, Mavroudis D, Kourousis C, Kakolyris S, Vardakis N, Kalbakis K, Pallis A, Ardavanis A, Varveris C, Georgoulias V. Multicenter dose-finding study of concurrent capecitabine and radiotherapy as adjuvant treatment for operable rectal cancer. Int J Radiat Oncol Biol Phys. 2003 Aug 1;56(5):1284-7.</citation>
    <PMID>12873672</PMID>
  </reference>
  <reference>
    <citation>Ngan SY, Michael M, Mackay J, McKendrick J, Leong T, Lim Joon D, Zalcberg JR. A phase I trial of preoperative radiotherapy and capecitabine for locally advanced, potentially resectable rectal cancer. Br J Cancer. 2004 Sep 13;91(6):1019-24.</citation>
    <PMID>15305186</PMID>
  </reference>
  <reference>
    <citation>Dunst J, Reese T, Sutter T, Zühlke H, Hinke A, Kölling-Schlebusch K, Frings S. Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer. J Clin Oncol. 2002 Oct 1;20(19):3983-91.</citation>
    <PMID>12351595</PMID>
  </reference>
  <reference>
    <citation>Rödel C, Grabenbauer GG, Papadopoulos T, Hohenberger W, Schmoll HJ, Sauer R. Phase I/II trial of capecitabine, oxaliplatin, and radiation for rectal cancer. J Clin Oncol. 2003 Aug 15;21(16):3098-104.</citation>
    <PMID>12915600</PMID>
  </reference>
  <reference>
    <citation>Fakih MG, Rajput A, Yang GY, Pendyala L, Toth K, Smith JL, Lawrence DD, Rustum YM. A Phase I study of weekly intravenous oxaliplatin in combination with oral daily capecitabine and radiation therapy in the neoadjuvant treatment of rectal adenocarcinoma. Int J Radiat Oncol Biol Phys. 2006 Aug 1;65(5):1462-70. Epub 2006 Jun 5.</citation>
    <PMID>16750332</PMID>
  </reference>
  <reference>
    <citation>Glynne-Jones R, Sebag-Montefiore D, Maughan TS, Falk SJ, McDonald AC. A phase I dose escalation study of continuous oral capecitabine in combination with oxaliplatin and pelvic radiation (XELOX-RT) in patients with locally advanced rectal cancer. Ann Oncol. 2006 Jan;17(1):50-6. Epub 2005 Nov 10.</citation>
    <PMID>16284060</PMID>
  </reference>
  <reference>
    <citation>Machiels JP, Duck L, Honhon B, Coster B, Coche JC, Scalliet P, Humblet Y, Aydin S, Kerger J, Remouchamps V, Canon JL, Van Maele P, Gilbeau L, Laurent S, Kirkove C, Octave-Prignot M, Baurain JF, Kartheuser A, Sempoux C. Phase II study of preoperative oxaliplatin, capecitabine and external beam radiotherapy in patients with rectal cancer: the RadiOxCape study. Ann Oncol. 2005 Dec;16(12):1898-905. Epub 2005 Oct 11.</citation>
    <PMID>16219623</PMID>
  </reference>
  <reference>
    <citation>Schmoll HJ, Cartwright T, Tabernero J, Nowacki MP, Figer A, Maroun J, Price T, Lim R, Van Cutsem E, Park YS, McKendrick J, Topham C, Soler-Gonzalez G, de Braud F, Hill M, Sirzén F, Haller DG. Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: a planned safety analysis in 1,864 patients. J Clin Oncol. 2007 Jan 1;25(1):102-9.</citation>
    <PMID>17194911</PMID>
  </reference>
  <reference>
    <citation>De Paoli A, Chiara S, Luppi G, Friso ML, Beretta GD, Del Prete S, Pasetto L, Santantonio M, Sarti E, Mantello G, Innocente R, Frustaci S, Corvò R, Rosso R. Capecitabine in combination with preoperative radiation therapy in locally advanced, resectable, rectal cancer: a multicentric phase II study. Ann Oncol. 2006 Feb;17(2):246-51. Epub 2005 Nov 9.</citation>
    <PMID>16282246</PMID>
  </reference>
  <reference>
    <citation>Rödel F, Hoffmann J, Grabenbauer GG, Papadopoulos T, Weiss C, Günther K, Schick C, Sauer R, Rödel C. High survivin expression is associated with reduced apoptosis in rectal cancer and may predict disease-free survival after preoperative radiochemotherapy and surgical resection. Strahlenther Onkol. 2002 Aug;178(8):426-35.</citation>
    <PMID>12240548</PMID>
  </reference>
  <reference>
    <citation>Ruzzo A, Graziano F, Loupakis F, Rulli E, Canestrari E, Santini D, Catalano V, Ficarelli R, Maltese P, Bisonni R, Masi G, Schiavon G, Giordani P, Giustini L, Falcone A, Tonini G, Silva R, Mattioli R, Floriani I, Magnani M. Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy. J Clin Oncol. 2007 Apr 1;25(10):1247-54. Erratum in: J Clin Oncol. 2009 Jul 1;27(19):3262.</citation>
    <PMID>17401013</PMID>
  </reference>
  <reference>
    <citation>Gordon MA, Gil J, Lu B, Zhang W, Yang D, Yun J, Schneider S, Groshen S, Iqbal S, Press OA, Rhodes K, Lenz HJ. Genomic profiling associated with recurrence in patients with rectal cancer treated with chemoradiation. Pharmacogenomics. 2006 Jan;7(1):67-88.</citation>
    <PMID>16354126</PMID>
  </reference>
  <reference>
    <citation>Stoehlmacher J, Park DJ, Zhang W, Yang D, Groshen S, Zahedy S, Lenz HJ. A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer. Br J Cancer. 2004 Jul 19;91(2):344-54.</citation>
    <PMID>15213713</PMID>
  </reference>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 9, 2008</study_first_submitted>
  <study_first_submitted_qc>July 10, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 14, 2008</study_first_posted>
  <last_update_submitted>February 15, 2016</last_update_submitted>
  <last_update_submitted_qc>February 15, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 17, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese Academy of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Jing Jin, M.D.</investigator_full_name>
    <investigator_title>M.D.</investigator_title>
  </responsible_party>
  <keyword>rectal cancer</keyword>
  <keyword>concurrent chemoradiotherapy</keyword>
  <keyword>adjuvant therapy</keyword>
  <keyword>phase III study</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

